Sperm protein 17 expression by murine epithelial ovarian cancer cells and its impact on tumor progression

Gao, Q, Xiang, S, Wilson, K, Madondo, M, Stephens, A and Plebanski, M 2018, 'Sperm protein 17 expression by murine epithelial ovarian cancer cells and its impact on tumor progression', Cancers, vol. 10, no. 8, pp. 1-15.


Document type: Journal Article
Collection: Journal Articles

Title Sperm protein 17 expression by murine epithelial ovarian cancer cells and its impact on tumor progression
Author(s) Gao, Q
Xiang, S
Wilson, K
Madondo, M
Stephens, A
Plebanski, M
Year 2018
Journal name Cancers
Volume number 10
Issue number 8
Start page 1
End page 15
Total pages 15
Publisher MDPIAG
Abstract The cancer testis antigen sperm protein 17 (Sp17) is a promising antigenic target in epithelial ovarian cancer (EOC) vaccine development. However, its role in ovarian cancer is unclear. We isolated and expanded Sp17+ and Sp17- clones from the murine EOC cell line ID8, and compared their in-vitro cell growth characteristics and in-vivo tumorigenicity. We also examined the potential co-expression of molecules that may influence cancer cell survival and interaction with immune cells. These include stimulatory and immunosuppressive molecules, such as major histocompatibility class I molecules (MHC I), MHC II, cytotoxic T lymphocyte associated antigen-4 (CTLA-4), CD73, CD39, tumor necrosis factor receptor II (TNFRII), signal transducer and activator of transcription 3 (STAT3) and programmed death-ligand 1 (PD-L1). Whilst the presence of Sp17 was not correlated with the ID8 cell proliferation/growth capacity in vitro, it was critical to enable progressive tumor formation in vivo. Flow cytometry revealed that Sp17+ ID8 cells displayed higher expression of both STAT3 and PD-L1, whilst MHC II expression was lower. Moreover, Sp17high (PD-L1+ MHCII-) cell populations showed significantly enhanced resistance to Paclitaxel-induced cell death in vitro compared to Sp17low (PD-L1- MHCII+) cells, which was associated in turn with increased STAT3 expression. Together, the data support Sp17 as a factor associated with in-vivo tumor progression and chemo-resistance, validating it as a suitable target for vaccine development.
Subject Tumour Immunology
Cancer Therapy (excl. Chemotherapy and Radiation Therapy)
Keyword(s) ID8
Immune evasion
MHC II
Paclitaxel
PD-l1
Sperm protein 17 (Sp17)
STAT3
Tumor resistant
DOI - identifier 10.3390/cancers10080276
Copyright notice © 2018 by the authors. Licensee MDPI, Basel, Switzerland.
ISSN 2072-6694
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Altmetric details:
Access Statistics: 5 Abstract Views  -  Detailed Statistics
Created: Thu, 31 Jan 2019, 11:26:00 EST by Catalyst Administrator
© 2014 RMIT Research Repository • Powered by Fez SoftwareContact us